{{Rsnum
|rsid=7668666
|Gene=TLR3
|Chromosome=4
|position=186080138
|Orientation=plus
|GMAF=0.2332
|Gene_s=TLR3
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 4.4 | 36.3 | 59.3
| HCB | 13.3 | 40.7 | 45.9
| JPT | 16.8 | 45.1 | 38.1
| YRI | 1.4 | 16.3 | 82.3
| ASW | 0.0 | 24.6 | 75.4
| CHB | 13.3 | 40.7 | 45.9
| CHD | 4.7 | 46.7 | 48.6
| GIH | 5.9 | 38.6 | 55.4
| LWK | 0.0 | 15.6 | 84.4
| MEX | 6.9 | 32.8 | 60.3
| MKK | 1.9 | 25.6 | 72.4
| TSI | 9.8 | 32.4 | 57.8
| HapMapRevision=28
}}{{PMID Auto
|PMID=23462921
|Title=Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression
|OA=1
}}

{{PMID Auto
|PMID=22912896
|Title=HLA-A*0206 with TLR3 polymorphisms exerts more than additive effects in Stevens-Johnson syndrome with severe ocular surface complications.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}